Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Nov 11, 2019 $111.45 $111.74 $111.25 $111.39 426 349
Nov 08, 2019 $111.75 $111.89 $111.30 $111.58 397 538
Nov 07, 2019 $111.62 $111.95 $111.42 $111.55 333 262
Nov 06, 2019 $111.65 $112.37 $111.08 $111.67 507 938
Nov 05, 2019 $110.17 $112.89 $109.67 $111.75 694 951
Nov 04, 2019 $110.08 $110.10 $109.69 $110.06 263 386
Nov 01, 2019 $109.31 $110.00 $108.64 $109.90 472 075
Oct 31, 2019 $108.14 $109.43 $108.00 $109.17 464 381
Oct 30, 2019 $109.13 $109.31 $108.25 $108.27 790 502
Oct 29, 2019 $109.46 $109.87 $108.80 $108.99 798 962
Oct 28, 2019 $109.66 $110.21 $109.00 $109.46 653 649
Oct 25, 2019 $108.75 $109.96 $108.48 $109.00 1 963 119
Oct 24, 2019 $100.97 $112.50 $99.41 $108.64 3 347 348
Oct 23, 2019 $99.92 $101.18 $99.64 $101.04 505 963
Oct 22, 2019 $98.94 $100.70 $98.75 $100.20 518 953
Oct 21, 2019 $100.60 $100.91 $99.65 $100.82 222 267
Oct 18, 2019 $101.32 $101.39 $99.92 $100.04 348 303
Oct 17, 2019 $100.58 $101.50 $99.90 $100.99 365 668
Oct 16, 2019 $98.80 $100.55 $98.67 $100.12 392 948
Oct 15, 2019 $98.68 $99.92 $98.33 $99.08 165 623
Oct 14, 2019 $99.78 $100.16 $98.31 $98.67 192 223
Oct 11, 2019 $96.72 $101.40 $96.01 $99.79 1 030 131
Oct 10, 2019 $98.00 $98.46 $95.93 $96.25 450 716
Oct 09, 2019 $97.89 $98.60 $97.03 $98.01 190 741
Oct 08, 2019 $97.77 $98.37 $96.66 $97.69 257 667
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT